

Hikma Appoints Global Head of Intellectual Property and US General Counsel

Eatontown, NJ, October 4, 2018 – Hikma Pharmaceuticals PLC (Hikma, Group) (LSE: HIK) (NASDAQ Dubai: HIK) (OTC: HKMPY) (rated Ba1 Moody's / BB+ S&P, both stable) today announced the appointment of Samuel (Sam) Park as Global Head of Intellectual Property (IP) and General Counsel for the US, effective immediately.

Mr. Park joins Hikma from Winston & Strawn LLP where he advised leading pharmaceutical companies on a variety of legal and intellectual property issues, from determining the appropriate IP strategies to litigating patent-protected pharmaceutical products. Mr Park will be based in the US.

Commenting on the appointment, Hussein Arkhagha, Hikma's global General Counsel, said, "We are very excited that Sam has joined Hikma. He brings a wealth of legal experience and has an impressive record of challenging patents. Sam will play a pivotal role in enhancing our R&D program, enabling us to bring more differentiated products to the market."

Commenting on his appointment, Mr. Park said, "Hikma has a strong legacy and has been investing in its people and capabilities to prepare for its next phase of growth. I share the company's enthusiasm for the future and look forward to helping Hikma achieve its ambitions."

Mr. Parks holds a B.A. in Biological Sciences from the University of Chicago and a J.D., magna cum laude, from Loyola University School of Law. He is licensed to practice in Illinois, New Jersey, New York, and the United States Patent & Trademark Office.

END

Contact:

Hikma Pharmaceuticals PLC

Steven Weiss

Senior Director, Communications and Public Affairs

Office: 732-720-2830, Mobile: 732-788-8279

sweiss@hikma.com

About Hikma

Hikma helps put better health within reach every day for millions of people in more than 50 countries around the world. For 40 years, we've been creating high-quality medicines and making them accessible to the people who need them. We're a global company with a local presence across the United States (US), the Middle East and North Africa (MENA) and Europe, and we use our unique insight and expertise to transform cutting-edge science into innovative solutions that transform people's lives. We're committed to our customers, and the people they care for, and by thinking creatively and acting practically, we provide them with a broad range of branded and nonbranded generic medicines. Together, our 8,500 colleagues are helping to shape a healthier world that enriches all our communities. We are a leading licensing partner in the MENA region, and through our venture capital arm, are helping bring innovative health technologies to people around the world. For more information, please visit www.hikma.com.